Genetic Polymorphisms of CYP24A1 Gene and Cancer Susceptibility: a Meta-analysis Including 40640 Subjects

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2023 Sep 5

PMID 37670334

Authors

Yubin Wang

Ruiwen Wang

Shaofei Yuan

Xiaotang Liu

Affiliations

Soon will be listed here.

Abstract

Background: Whether cytochrome P450 24A1 (CYP24A1) polymorphism is associated with cancer susceptibility, the individual study results are still controversial. Therefore, we performed a comprehensive study to identify the association of CYP24A1 polymorphisms (rs4809960, rs6068816, rs2296241, rs4809957, rs2762939) with cancer susceptibility.

Methods: Electronic databases including Cochrane Library, PubMed, and Embase were systematically retrieved for relevant publications. Fixed or random-effect model was selected to calculate odds ratios (ORs) with their 95% confidence intervals (95%CI).

Results: Eighteen published articles were identified. The results indicated that rs4809960 polymorphism was associated with a decreased cancer risk in Caucasian (TT vs. TC+CC: P=0.035; C vs. T: P=0.016) and Asian population (CC vs. TC+TT: OR P=0.044; TT vs. TC+CC: P=0.021; CC vs. TT: P=0.020; C vs. T: P=0.008) and breast cancer risk (TT vs. TC+CC: P = 0.007; TC vs. TT: P=0.004; C vs. T: P=0.033). A significant association was found between rs2296241 polymorphism and esophageal squamous cell carcinoma risk (AA vs. GG+AG: P = 0.023) and prostate cancer susceptibility (A vs. G: P=0.022). Furthermore, rs4809957 polymorphism was associated with prostate cancer susceptibility in Caucasian (GG vs. GA+AA: P=0.029; GA vs. GG: P=0.022) and breast cancer susceptibility (AA vs. GG+GA: P=0.012; AA vs. GG, P=0.010; A vs. G: P=0.024). Additionally, rs6068816 polymorphism significantly decreased the lung cancer (CC vs. CT+TT: P = 0.016; TT vs. CC: P = 0.044; CT vs. CC: P = 0.036; T vs. C: P = 0.016) and breast cancer risk (TT vs. CC+CT: P = 0.043; TT vs. CC: P = 0.039). No association was found for rs2762939 polymorphism with overall cancer risk. However, for rs2296241, rs4809957, and rs6068816 polymorphisms, there were no significant differences after the Bonferroni correction.

Conclusion: The meta-analysis suggested that rs4809960 was associated with cancer risk and might be a genetic marker for predicting cancer risk. More large-scale and large-sample studies are necessary to further confirm these results.

References

Oh J, Byun S, Lee S, Hong S, Jeong C, Choi W . Genetic variants in the CYP24A1 gene are associated with prostate cancer risk and aggressiveness in a Korean study population. Prostate Cancer Prostatic Dis. 2014; 17(2):149-56. DOI: 10.1038/pcan.2014.1. View

Parise R, Egorin M, Kanterewicz B, Taimi M, Petkovich M, Lew A . CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer. 2006; 119(8):1819-28. DOI: 10.1002/ijc.22058. View

Holick M . Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006; 92(1):49-59. DOI: 10.1016/j.pbiomolbio.2006.02.014. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Anderson L, Cotterchio M, Cole D, Knight J . Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev. 2011; 20(8):1708-17. DOI: 10.1158/1055-9965.EPI-11-0300. View

Koberle B, Koch B, Fischer B, Hartwig A . Single nucleotide polymorphisms in DNA repair genes and putative cancer risk. Arch Toxicol. 2016; 90(10):2369-88. DOI: 10.1007/s00204-016-1771-2. View

Shiratsuchi H, Wang Z, Chen G, Ray P, Lin J, Zhang Z . Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma. J Thorac Oncol. 2016; 12(2):269-280. DOI: 10.1016/j.jtho.2016.10.010. View

Penna-Martinez M, Ramos-Lopez E, Stern J, Kahles H, Hinsch N, Hansmann M . Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma. Thyroid. 2012; 22(7):709-16. PMC: 3387756. DOI: 10.1089/thy.2011.0330. View

Holick C, Stanford J, Kwon E, Ostrander E, Nejentsev S, Peters U . Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(10):1990-9. DOI: 10.1158/1055-9965.EPI-07-0487. View

10.

Deeb K, Trump D, Johnson C . Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007; 7(9):684-700. DOI: 10.1038/nrc2196. View

11.

Armstrong R . When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014; 34(5):502-8. DOI: 10.1111/opo.12131. View

12.

Sun H, Wang C, Hao M, Sun R, Wang Y, Liu T . CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer. Hum Pathol. 2016; 50:101-8. DOI: 10.1016/j.humpath.2015.11.008. View

13.

Wang P, Zhang H, Zhang Z, Qin L, Li B . Association of the CYP24A1-rs2296241 polymorphism of the vitamin D catabolism enzyme with hormone-related cancer risk: a meta-analysis. Onco Targets Ther. 2015; 8:1175-83. PMC: 4447172. DOI: 10.2147/OTT.S80311. View

14.

Gong C, Long Z, Yu Y, Zhu L, Tian J, Li S . Dietary factors and polymorphisms in vitamin D metabolism genes: the risk and prognosis of colorectal cancer in northeast China. Sci Rep. 2017; 7(1):8827. PMC: 5562792. DOI: 10.1038/s41598-017-09356-1. View

15.

Holt S, Kwon E, Peters U, Ostrander E, Stanford J . Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2009; 18(6):1929-33. PMC: 2743676. DOI: 10.1158/1055-9965.EPI-09-0113. View

16.

Feldman D, Krishnan A, Swami S, Giovannucci E, Feldman B . The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14(5):342-57. DOI: 10.1038/nrc3691. View

17.

Wu X, Cheng J, Yang K . Vitamin D-Related Gene Polymorphisms, Plasma 25-Hydroxy-Vitamin D, Cigarette Smoke and Non-Small Cell Lung Cancer (NSCLC) Risk. Int J Mol Sci. 2016; 17(10). PMC: 5085630. DOI: 10.3390/ijms17101597. View

18.

Wei Y, Wang X, Zhang Z, Xie M, Li Y, Cao H . Role of Polymorphisms of FAM13A, PHLDB1, and CYP24A1 in Breast Cancer Risk. Curr Mol Med. 2019; 19(8):579-588. DOI: 10.2174/1566524019666190619125109. View

19.

Sadeghi H, Nazemalhosseini-Mojarad E, Piltan S, Fazeli E, Moradi Y, Amin-Beidokhti M . A candidate intronic gene variant affects the risk of colorectal cancer. Biomark Med. 2019; 14(1):23-29. DOI: 10.2217/bmm-2019-0189. View

20.

Jones G, Prosser D, Kaufmann M . 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys. 2011; 523(1):9-18. DOI: 10.1016/j.abb.2011.11.003. View